




Amarin Corporation plc  
Investor Relations Department  
2 Pembroke House, Upper  
Pembroke  
Street 28-32  
Dublin 2  
Ireland

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

**NASDAQ: AMRN**

Last Trade:	2.92
Trade Time:	4:00 PM ET May 23, 2017
Change:	-0.05  (-1.684%)
Day Range	2.91 - 2.97
52-Week Range	1.77 - 3.65
Volume	1,161,082

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.


## Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

May 18, 2017

[Amarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular Care](#)

May 3, 2017

[Amarin Reports First Quarter 2017 Financial Results and Provides Update on Operations](#)

Apr 25, 2017

[Amarin to Report First Quarter 2017 Results and Host Conference Call on May 3, 2017](#)

Mar 21, 2017

[Amarin Corporation CEO, John Thero, to Chair the American Heart Association's Heart & Stroke Ball in New York City](#)

Mar 16, 2017

[Amarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Adverse Cardiovascular Events Within the REDUCE-IT Study](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

Mar 1, 2017

[Annual Report \(10-K\)](#)

Apr 21, 2017

[Proxy Statement \(DEF 14A\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)

Nov 3, 2016

[Quarterly Report \(10-Q\)](#)

Aug 4, 2016

[Quarterly Report \(10-Q\)](#)